| 000 | 02812naaaa2200661uu 4500 | ||
|---|---|---|---|
| 001 | https://directory.doabooks.org/handle/20.500.12854/68341 | ||
| 005 | 20220220061557.0 | ||
| 020 | _abooks978-3-03943-918-8 | ||
| 020 | _a9783039439171 | ||
| 020 | _a9783039439188 | ||
| 024 | 7 |
_a10.3390/books978-3-03943-918-8 _cdoi |
|
| 041 | 0 | _aEnglish | |
| 042 | _adc | ||
| 072 | 7 |
_aM _2bicssc |
|
| 100 | 1 |
_aAquaro, Stefano _4edt |
|
| 700 | 1 |
_aAquaro, Stefano _4oth |
|
| 245 | 1 | 0 | _aFeatures of Pathogenesis of Human Viral Infections and Antiviral Drugs |
| 260 |
_aBasel, Switzerland _bMDPI - Multidisciplinary Digital Publishing Institute _c2021 |
||
| 300 | _a1 electronic resource (84 p.) | ||
| 506 | 0 |
_aOpen Access _2star _fUnrestricted online access |
|
| 520 | _aAmong infectious diseases, viral infections are the leading cause of death worldwide, especially in the most low-income countries, particularly in young children. Most of the human viruses are all well characterized in terms of structure, life-cycle, tropism, and associated primary pathologies, but many of the pathogenetic mechanisms underlying their ability to cause acute infection, persist or reactivate in the host and cause chronic and/or degenerative damage, and still need to be fully clarified. At the same time, it seems necessary to develop novel therapeutic approaches and rationale, and possibly more potent antiviral compounds that are addressed to novel targets. | ||
| 540 |
_aCreative Commons _fhttps://creativecommons.org/licenses/by/4.0/ _2cc _4https://creativecommons.org/licenses/by/4.0/ |
||
| 546 | _aEnglish | ||
| 650 | 7 |
_aMedicine _2bicssc |
|
| 653 | _ahRSV | ||
| 653 | _aF gene | ||
| 653 | _aG gene | ||
| 653 | _achildren | ||
| 653 | _arespiratory diseases | ||
| 653 | _agenotyping | ||
| 653 | _aSaudi Arabia | ||
| 653 | _aα chemokine receptor 4 | ||
| 653 | _aβ-chemokine receptor 5 | ||
| 653 | _ahuman immunodeficiency virus | ||
| 653 | _amonocyte-derived macrophages | ||
| 653 | _aHPV | ||
| 653 | _asexually transmitted diseases (STDs) | ||
| 653 | _alaboratory methods | ||
| 653 | _aPCR | ||
| 653 | _agenotypes | ||
| 653 | _asurveillance | ||
| 653 | _aepidemiology | ||
| 653 | _aexopolysaccharides | ||
| 653 | _alactic acid bacteria | ||
| 653 | _ahuman adenovirus type 5 | ||
| 653 | _aantiviral activity | ||
| 653 | _acell cycle | ||
| 653 | _aprevalence | ||
| 653 | _ahepatitis B virus | ||
| 653 | _agenotype | ||
| 653 | _abahrain | ||
| 653 | _asRAGE | ||
| 653 | _aoxidative stress | ||
| 653 | _ainflammation | ||
| 653 | _awarts | ||
| 856 | 4 | 0 |
_awww.oapen.org _uhttps://mdpi.com/books/pdfview/book/3351 _70 _zDOAB: download the publication |
| 856 | 4 | 0 |
_awww.oapen.org _uhttps://directory.doabooks.org/handle/20.500.12854/68341 _70 _zDOAB: description of the publication |
| 999 |
_c70051 _d70051 |
||